Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay.

Hao-Kuen LinThuy CanAdriana KahnCynthia A FlanneryJess HoagAlekhya AkkunuriHelen BaileyRick BaehnerLajos PusztaiMariya Rozenblit

Published in: The oncologist (2023)

Cancers with higher mRNA levels exist within IHC 0 and low categories, most of the HER2-low patients by IHC have low RS indicating no benefit from current adjuvant chemotherapies.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
early stage
high resolution
prognostic factors
high throughput
young adults
patient reported outcomes
patient reported